Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06618196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

StatusUnknown
PhasePhase 2
SponsorLG Chem
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 1, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
LG Chem
13 trials monitored
See 1 trial at risk
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.
Trial Details
NCT Number NCT06618196
Lead Sponsor LG Chem
Conditions
(from sponsor)		 Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection
Related terms Diphtheria, Haemophilus Infections, Hepatitis B, Poliomyelitis, Tetanus, Whooping Cough
Enrollment 336 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov